Drug shrinks tumors in children with brain cancer in early trial; FDA approved more cancer drugs than EMA

Day One Biopharmaceuticals reported that an experimental molecule shrank tumors by at least 50% in a majority of children in a Phase 2 trial. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by        STAT+: In early trial, drug shrinks tumors in majority of children with most common form of brain cancer By Jason Mast Adobe The results of Day One's brain cancer drug are an early but rare glimmer of progress in a disease that has seen little in the last 30 years. Read More STAT+: Quantity over quality: FDA approved more cancer drugs than EMA, but they may not have always benefited patients By Ed Silverman Molly Ferguson for STAT The FDA greatly outpaced its European counterpart in reviewing and approving new cancer treatments over a recent 10-year period. Read More STAT+: Watch: An interview with the FDA's top cancer regulator By Matthew Herper FDA Rich Pazdur, the director of the FDA Oncology Center of Excellence, addressed rapid approvals, diversity in clinical trials, and more. Read More Sponsor content by Genentech Over a decade later, what's next for the future of immunotherapy? Since 2011, the FDA has approved over three dozen novel immunotherapy treatments for patients with various forms of cancer. While these therapies have improved outcomes for some patients, there are others whose tumors don't respond well enough to these medicines. Learn how the next generation and personalization of immunotherapies will help deliver more options for people with cancer. STAT+: How high? Prices for newly launched medicines rose 20% annually, analysis finds By Ed Silverman Adobe “The numbers are stunning,” said Ira Loss of Washington Analysis, who tracks regulatory and legislative developments affecting drug companies. Read More Listen: Applause-worthy cancer data, the long wait for Novavax, & the next FDA controversy By Damian Garde and Meg Tirrell and Adam Feuerstein With the world's largest cancer conference just concluded, we explain the most important data presented at the meeting. Read More Tuesday, June 14, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser